Login to Your Account



Other News To Note


Monday, January 23, 2012
• Carolus Therapeutics Inc., of San Diego, published preclinical data showing CT-2009 prevented lung damage in multiple mouse models of acute lung injury. The molecule is designed to disrupt heteromers formed by the chemokines CCL5 (RANTES) and CXCL4, interfering with recruitment of neutrophils and tissue damage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription